Research
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unclear etiology, with a prevalence as high as 1 in 2,500 women (Bernatsky et al. 2007 ). It is characterized by an overactive immune system that targets normal tissue in nearly any body organ. The resulting inflammation causes dysfunction and damage; involvement of major organs such as the kidneys can be par ticularly devastating and even lifethreatening (Bernatsky et al. 2007 ).
The factors driving SLE are complex, but it is clear that there are definite, albeit illdefined, exogenous triggers. Different possible environ mental triggers have been considered, but at present there are relatively few relevant studies (Parks and Cooper 2006) and essentially no work has examined the effect of air pollution on SLE manifestations. This is an important knowledge gap, because there is a growing interest in pollution emissions and particulate matter (PM) exposures and their effects on health. This interest stems from recent data that have suggested that these exposures may be important triggers of systemic inflammation that could have important effects in terms of autoimmunity. Recent data have suggested that these exposures may be important triggers of systemic inflammation [for a review, see U.S. Environmental Protection Agency (EPA) 2004] that could have important effects in terms of autoimmunity.
Our aim in this study was to evaluate the potential influence of PM air pollution on the clinical course of SLE. We have focused on the effects of variations in levels of fine ambient PM with median aerodynamic diam eter ≤ 2.5 µm (PM 2.5 ). The main sources of PM 2.5 in the region of the study include road vehicle emissions and industrial emissions. Such small particles enter the body through airways and can affect immune system pathways (U.S. EPA 2004).
Materials and Methods
Subjects and overview of health assessments. We studied subjects who were followed in a clinical registry at the Lupus Clinic of the McGill University Health Centre (MUHC). All patients in this registry cohort fulfilled the revised American College of Rheumatology (ACR) criteria for SLE (Hochberg 1997; Tan et al. 1982) . Subjects in the cohort completed an annual evaluation that consisted of a review of symptoms, medications, physical find ings, and laboratory testing. The data were used to construct validated measures of disease activity [SLE Disease Activity Index, version 2000 (SLEDAI2K)] (Gladman et al. 2002) and damage [Systemic Lupus International Collaborating Clinics/ACR Damage Index (SLICC/ACR)] (Gladman et al. 2002) . The SLEDAI2K is a "weighted" index that provides a measurement of disease activity of the organ systems in SLE over a 10day period before the annual evaluation. The index includes central nervous system features, vascular involvement, kidney disease, musculo skeletal disease, dermatological features, serosal involvement, immune system activity, hema tological features, and constitutional symp toms (see Appendix). Theoretically, patients can score a maximum of 105, but in prac tice, scores greater than 45 are unusual. In the present study, we analyzed data collected on patients who resided on the island of Montreal (Quebec, Canada) and who were evaluated from January 2000 through September 2007. All subjects consented to be included in the registry, and studies were conducted under ethical approval from the MUHC.
We studied associations between PM 2.5 and the SLEDAI2K total score. We were also specifically interested in the presence or absence of renal tubule cellular casts, which are a marker for severe kidney inflammation related to SLE, and the presence or absence of antibodies against doublestranded DNA Background: Systemic lupus erythematosus (SLE) is a chronic disease of unclear etiology, characterized by an overactive immune system and the production of antibodies that may target normal tissues of many organ systems, including the kidneys. It can arise at any age and occurs mainly in women. oBjective: Our aim was to evaluate the potential influence of particulate matter (PM) air pollution on clinical aspects of SLE. Methods: We studied a clinic cohort of SLE patients living on the island of Montreal, followed annually with a structured clinical assessment. We assessed the association between ambient levels of fine PM [median aerodynamic diameter ≤ 2.5 μm (PM 2.5 )] measured at fixed-site monitoring stations and SLE disease activity measured with the SLE Disease Activity Index, version 2000 (SLEDAI-2K), which includes anti-double-stranded DNA (anti-dsDNA) serum-specific auto antibodies and renal tubule cellular casts in urine, which reflects serious renal inflammation. We used mixed effects regression models that we adjusted for daily ambient temperatures and ozone levels. (antidsDNA). AntidsDNA antibodies are specific for SLE, although they are not pres ent in all patients, and correlate with various types of system involvement (musculoskele tal, hematological, immunological, and, most important, renal disease) (Mosca et al. 2006 ). In the clinical setting, serial measurements of antidsDNA antibodies are routinely performed to identify and predict SLE activity and disease flareups, although the utility of this approach in decision making and treatment remains under discussion (Tseng et al. 2006) .
Disease activity measurements. The physical examinations of the SLE patients were performed by a specialist physician who (along with the patient) was blinded to the potential associations (pollution and disease activity) being tested. Hematological and immuno logical manifestations of SLE (including the presence or absence of antidsDNA anti bodies) were evaluated using venous periph eral blood samples collected between 0830 and 1130 hours on the day of the assessment. Urinalyses (to assess kidney disease, includ ing microscopic observation of casts) were done on freshly voided specimens. The pres ence of antidsDNA was assessed, up to 2007, using a radioimmunoassay method based on the Farr technique (Manthorpe et al. 1978) . Thereafter, an enzymelinked immunosorbent assay technique was used (Farrzyme human highavidity antidsDNA enzyme immuno assay kit; Binding Site, Birmingham, UK).
We studied the two specific laboratory measures (antidsDNA antibodies and renal casts, both of which contribute to the SLEDAI2K total score) because they are well known as important markers of the most active and severe forms of SLE and may represent more objective elements of SLE activity (as opposed to the musculoskeletal manifestation of arthritis for example, which may be a subtle or even subjective finding). Furthermore, these laboratory elements were measured specifically on the day of the clini cal evaluation, in contrast with other compo nents of the SLEDAI2K (e.g., dermatological manifestations and oral ulcers) that are scored positive if a patient reports that they were present at any time within the 10 days before the clinicial evaluation, even if they are absent at the time of the annual examination.
Measures of ambient PM 2.5 and ozone levels. Hourly measurements at fixedsite monitoring stations on the island of Montreal were obtained from the Environment Canada's National Air Pollution Surveillance network (http://www.etccte.ec.gc.ca/napsdata). The networks use taperedelement oscillating microbalance and beta attenuation monitor samplers (Ville de Montréal 2010) for PM 2.5 measurements and ultraviolet absorption ana lyzers for ozone. Hourly PM 2.5 concentrations were averaged across all Montreal stations; these mean hourly levels, averaged for the 24 hr preceding each clinical evaluation (from 1000 hours the day before the clinical evaluation to 0900 hours the day of the evaluation) and for up to 10 days before, were assigned to each patient. Ozone levels on the days before the evaluation dates were averaged over the 8 hr from 0900 to 1700 hours because ozone levels are highest during these hours. The median numbers of monitoring stations used to com pute the daily PM 2.5 and ozone concentrations were 7 and 10, respectively.
Outdoor ambient temperatures. We com puted the mean of the outdoor temperatures for the 24 hr preceding each clinic evaluation and for prior days (from 1000 hours the day before the clinical evaluation to 0900 hours the day of the evaluation). Hourly tempera ture data were acquired from the Environment Canada Meteorological Centre located at the Pierre Elliott Trudeau International Airport (Dorval, Quebec, Canada), about 20 km from the city core (Environment Canada 2010) .
Analysis. To analyze associations between PM 2.5 exposure levels and SLEDAI2K total score, antidsDNA antibodies, and uri nary casts, we used random intercept models for repeatedmeasures (longitudinal) data to account for correlations among repeated measures within individuals. Thus, the inter pretation of reported estimates is at the subject level. We used negative binomial mixed models for SLEDAI2K total score and logistic mixed models to estimate associations with binary outcome variables (antidsDNA and renal casts). The SLEDAI2K score is a discrete and an asymmetrical variable. As overdispersion was present in the distribution of this variable (likelihood ratio test, p < 0.001) that precluded the use of a Poisson model, so we used a nega tive binomial model. Measures of association [incidence rate ratios (IRRs) for SLEDAI2K scores and odds ratios (ORs) for antidsDNA and renal casts] and their 95% confidence intervals (CIs) are presented as associations per 10µg/m 3 increases in PM 2.5 levels. Adjusted models included ozone levels [a potential risk factor for inflammation (e.g., Khatri et al. 2009 ) that may vary with PM 2.5 ] and ambient temperatures (to account for seasonal effects) averaged over the same time window as PM 2.5 .
Components of the SLEDAI2K could be scored positive if present at any time within the 10 days preceding the assessment. Thus, to assess exposure-response relationships for total SLEDAI2K scores, we assessed effects not only for PM 2.5 levels on the day before the evaluation (average of hourly levels measured from 1000 hours the day before to 0900 hours on the day of the visit), but also for hourly averages of up to 10 days before the visit.
Age at SLE onset, age at time of physi cian assessment, smoking (ever vs. never), race/ethnicity (with separate dummy vari ables for Caucasian, black, or Asian), edu cation (whether or not the subject had any secondary schooling vs. ≤ 11 years), and daily use of immunomodulatory drugs (hydroxy chloroquine, mycophenolate, oral or parenteral methotrexate, azathioprine, and prednisone) were evaluated as potential effect modifiers by adding product terms between each factor and PM 2.5 to models. The effects Data are reported as mean ± SD or n (%). a Eight subjects were missing smoking status. b Thirty-five subjects were missing education level. Total SLEDAI-2K score (n = 1,003) 4.5 ± 4.8 (0-28) Anti-dsDNA, patient evaluations with positive assay (n = 957) 263 (27.5) Renal tubule casts present on urinalysis (n = 861) 81 (9.4) Disease damage SLICC/ACR score (n = 1,005) 1.9 ± 2.2 Environmental variables PM 2.5 (μg/m 3 ) 10.0 ± 7.8 (1.1-54.9) Ozone (μg/m 3 ) 47.7 ± 23.7 (2.3-137.7) Temperature (°C) 7.5 ± 11.4 (-21.5 to -28.8)
Data are reported as n (%) or mean ± SD (range).
of inter actions were tested with α = 0.05. These variables did not vary with PM 2.5 levels (data not shown) and so were not considered confounders. We performed all analyses with STATA (version 10.1; StataCorp LP, College Station, TX, USA).
Results
We studied 237 patients (223 women, 14 men) with a mean age at the time of their first MUHC visit of 41.2 years old (range, 18-83 years; Table 1 ). During the study period (January 2000-September 2007), each patient participated in an average of 4.6 assessments that averaged 409 days apart. For this period, the PM 2.5 levels rarely exceeded the PM 2.5 Canadian objective of 30 µg/m 3 ( Table 2 ). The intraclass correlation for the three outcome variables within individual patients ranged from 0.12 to 0.40. IRR estimates did not clearly demonstrate a relationship between a 10µg/m 3 increase in PM 2.5 and total SLEDAI2K scores ( Figure 1A ), although our results suggested some potential effect with PM 2.5 levels averaged over 10 days (not evident for PM 2.5 levels on the day before the evalua tion; crude IRR for PM 2.5 levels averaged over 6 days = 1.09; 95% CI, 0.99-1.20). Anti dsDNA and urinary casts were significantly associated with PM 2.5 levels shortly before the clinical visits (averaged over 24 or 48 hr before; Figure 1B ,C). The crude OR relative to an increase in PM 2.5 of 10 µg/m 3 (48hr averages) was 1.26 (95% CI, 0.96-1.65) for the presence of antidsDNA and 1.43 (95% CI, 1.05-1.95) for the presence of renal casts. Although not statistically significant, there was also a suggestion of some association between antidsDNA and PM 2.5 levels averaged over 10 days. Controlling for ambient temperatures and ozone levels had little influence (associa tion with PM 2.5 levels averaged over 48 hr: antidsDNA, OR = 1.34; 95% CI, 1.02-1.77; renal casts, OR = 1.28, 0.92-1.80). Including potential effect modifiers in the model (e.g., medications and race/ethnicity) and examina tions for interactions failed to clearly dem onstrate important or consistent effects at α = 0.05.
Discussion
To our knowledge, the results presented here are the first to suggest that autoimmune inflammatory diseases such as SLE may be associated with variations in air pollutant levels. These findings add to a multitude of studies that have consistently related the adverse health effects (both acute and chronic) of ambient fine PM (Brook 2008; CalderónGarcidueñas et al. 2008; Ghio et al. 2000; U.S. EPA 2004) . This study also adds weight to concerns that ambi ent air pollutants may be an important trigger of inflammation and autoimmunity.
Fine particles are believed to induce effects through inflammation and oxidative stress in the lungs when inhaled (U.S. EPA 2004). The smaller particles have also been suggested to enter the systemic circulation (Nemmar et al. 2002) , where they would be capable of caus ing widespread inflammation and oxidative stress (Shukla et al. 2000; U.S. EPA 2004) . The proinflammatory circulating cytok ines generated upon air pollution exposure (Shoenfelt et al. 2009; van Eeden et al. 2001; Watterson et al. 2007 ) could plausibly act to trigger and/or heighten autoimmune disease.
Interestingly, there are two recent stud ies that have suggested road traffic and pol lution as triggers of autoimmune rheumatic diseases in humans, such as juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA). In one study, Zeft et al. (2009) reported that increased concentrations of PM 2.5 and stagnant air conditions were associated with significantly elevated risk of the onset of JIA in young chil dren. In another study, Hart et al. (2009) found that the risk of onset of RA for participants in the Nurses' Health Study was higher for women who lived within 50 m of a major road than for those who lived 200 m or farther away; this finding suggests that pollution from traf fic is indeed an environmental risk factor for autoimmune diseases such as RA.
We observed associations between short term variations in PM 2.5 levels (averaged over 1-10 days) and antidsDNA and urinary casts that suggest acute effects. Although it is physiologically plausible for urinary casts and antidsDNA to vary on a daily basis with PM 2.5 levels, studies are needed to document the kinetics of these features and to sup port the observed associations. Such knowl edge could help the understanding of their Figure 1 . Associations between PM 2.5 levels averaged over the day before the medical evaluations (from 1000 hours the day before the evaluation to 0900 hours on the day of the evaluation) and up to the 10 days before, and SLEDAI-2K scores: total score (A), anti-dsDNA (B), and urinary casts (C). Associations are expressed per 10 μg/m 3 of PM 2.5 . In each pair of data points, the first represents crude estimates and the second coefficients adjusted for ozone and temperature levels at the same exposure window as PM 2.5 . Whiskers represent 95% CIs. We did not clearly demon strate an association between PM 2.5 and over all SLEDAI2K total scores; in part this may be due to the way the SLEDAI2K is scored and to the fact that some features of disease activity could have been present early in the 10day window preceding the assessment (but not actually present at the time of the visit).
Because the associations we observed were mainly with SLEDAI2K lab measures (i.e., urinary casts and antidsDNA), further studies are needed to address whether fine PM levels are mainly associated with renal lupus activity or with the general disease activity. There are several limitations associ ated with how we estimated exposure of our patients to PM 2.5 . We used PM 2.5 daily regional averages because we did not have access to personal exposure information. We assumed that all subjects were in Montreal for the 10 days before their visits, but we did not have information on their actual location. Furthermore, outdoor ambient PM 2.5 lev els may not adequately represent exposure of our patients because people are likely to spend most of their time indoors, where both indoor and outdoor PM 2.5 sources contribute to indoor levels (World Health Organization 2000) . Future studies on the association between shortterm variations in air pollu tion and inflammatory disease activity should address these limitations.
Because we did not study incident disease and because the patients under study were all from one tertiary care center, we cannot com ment on potential roles of longterm exposure or spatial variations in air pollution. Nor did we assess potential effects of pollution on the actual incidence of SLE. However, future work by our team, using populationbased administrative data, will explore these issues.
Conclusion
Our data suggest that shortterm variations in air pollution may influence disease activity in established autoimmune rheumatic disease in humans. Our results add weight to concerns that pollution may be an important trigger of inflammation and autoimmunity. Although further studies are needed to confirm these findings, we suspect that clinicians, health authorities, and patients may need to examine and address the potentially serious adverse health effects of pollution.
